May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Impact of Retinal Cysts on Outcomes in Patients With Diabetic Macular Edema Treated With Pegaptanib Sodium
Author Affiliations & Notes
  • M. Goldbaum
    (OSI) Eyetech, New York, New York
  • K. G. Csaky
    Duke University Medical Center, Durham, North Carolina
  • Footnotes
    Commercial Relationships  M. Goldbaum, (OSI) Eyetech, E; K.G. Csaky, (OSI) Eyetech, C.
  • Footnotes
    Support  Research supported by (OSI) Eyetech
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3465. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Goldbaum, K. G. Csaky; Impact of Retinal Cysts on Outcomes in Patients With Diabetic Macular Edema Treated With Pegaptanib Sodium. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3465. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the impact of the presence of retinal cysts on functional and anatomical outcomes in patients with diabetic macular edema (DME) treated with pegaptanib sodium.

Methods: : A randomized, double-masked, dose-ranging, phase 2 study, included subjects with visual acuity (VA) between 20/50 and 20/320 who suffered from clinically significant DME affecting the center of the macula, and who could safely defer photocoagulation therapy for 16 weeks. Intravitreous injections of pegaptanib (0.3, 1, or 3 mg) or sham injections were administered at baseline, weeks 6 and 12, and every 6 weeks following, up to week 30, if indicated, to a maximum of 6 injections. Macular photocoagulation was allowed after week 12 at the investigator’s discretion. Presence of retinal cysts was based on masked assessment of Optical Coherence Tomography (OCT) by an independent reading center.

Results: : At baseline, 59 pegaptanib-treated subjects had no retinal cyst on OCT and 57 had cysts. Mean VA at baseline was similar across groups (mean≈20/80), but on average, maculas with cysts were thicker than those without (500 µm vs. 418 µm). Mean changes from baseline to week 12 in VA and center point thickness were similar between those with (+3.9 letters; -23 µm) and without (+2.9 letters; -31 µm) cysts. In a subgroup analysis subjects with smaller cysts (n=12) had better anatomical outcomes at week 12 than subjects with larger ones (n=43), but similar visual results.

Conclusions: : In this preliminary analysis there was no clear signal that the response to pegaptanib in DME differs between cystic and non-cystic cases. Results of further analyses will be presented to investigate the effect of anti-VEGF therapy in different anatomic presentations of diabetic macular edema by OCT.

Clinical Trial: : NTC00040313

Keywords: diabetic retinopathy 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.